Drug Trial Radar · NCT00974974
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
Last checked: Nov 19, 2026Latest source record: Aug 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
471
Actual
Start
Sep 2009
Primary completion
Jan 2011
Study completion Mar 2011
Sponsor
- Lead sponsor
- Impax Laboratories, LLCIndustry
- Sponsor type
- Industry
- First posted
- Sep 11, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.
Conditions
- Parkinson's Disease
Interventions
IPX066Drug
extended-release carbidopa-levodopa capsules
IR CD-LDDrug
immediate-release carbidopa-levodopa tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of "Off" Time During Waking Hours at End of StudyTime frame: 22 weeks
Locations
73 sites in 8 countries. Site status is shown where the registry gives one.
Investigator 17
Birmingham, Alabama
Investigator 49
Phoenix, Arizona
Investigator 7
Little Rock, Arkansas
Investigator 3
La Jolla, California
Investigator 31
Sunnyvale, California
Investigator 6
Torrance, California
Investigator 51
Aurora, Colorado
Investigator 10
New Haven, Connecticut
Investigator 64
Bradenton, Florida
Investigator 61
Hollywood, Florida
Investigator 5
Ocala, Florida
Investigator 15
Port Charlotte, Florida
Investigator 8
Port Charlotte, Florida
Investigator 4
St. Petersburg, Florida
Investigator 46
Augusta, Georgia
Investigator 38
Boise, Idaho
Investigator 19
Chicago, Illinois
Investigator 40
Chicago, Illinois
Investigator 39
Des Moines, Iowa
Investigator 29
Kansas City, Kansas
Investigator 1
Bingham Farms, Michigan
Investigator 21
New Brunswick, New Jersey
Investigator 25
Albany, New York
Investigator 8
Commack, New York
Investigator 12
New York, New York
Investigator 11
Durham, North Carolina
Investigator 9
Raleigh, North Carolina
Investigator 20
Cincinnati, Ohio
Investigator 42
Toledo, Ohio
Investigator 60
Tulsa, Oklahoma
Investigator 14
Charleston, South Carolina
Investigator 16
Dallas, Texas
Investigator 13
Houston, Texas
Investigator 65
Tacoma, Washington
Investigator 2
Milwaukee, Wisconsin
Investigator 24
London, Ontario, Canada
Investigator 18
Ottawa, Ontario, Canada
Investigator 26
Québec, Quebec, Canada
Investigator 32
Strasbourg, Alsace, France
Investigator 22
Dijon, Bourgogne-Franche-Comté, France
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.